Does Benzene Cause Acute Myeloid Leukemia?

From General Health Education to Occupational Risk Assessment

The legacy theme of general health and science information has long served as a foundation for public understanding of environmental risks and their potential impacts on human well-being. Within this broad context, discussions of chemical exposures and their health consequences have typically emphasized universal precautions and broad-based safety guidelines. This heritage provides a necessary backdrop for examining more specific occupational scenarios where exposure levels and durations may differ substantially from general environmental contexts. Transitioning from this general health perspective, the focus now narrows to occupational environments where workers may encounter chemical agents at higher concentrations and with greater frequency than the general population. In industrial settings, particularly those involving mass production processes, the potential for sustained exposure to various compounds becomes a central concern. Among these compounds, benzene has received particular attention due to its widespread use in manufacturing and its classification as a hazardous substance. The occupational exposure concern centers on whether prolonged contact with benzene in workplace settings elevates the risk of developing specific health conditions. This inquiry moves beyond general health advisories to examine the relationship between benzene exposure and acute myeloid leukemia, a serious blood cancer. The transition from broad health education to targeted occupational risk assessment requires careful consideration of exposure pathways, duration, and intensity that characterize industrial environments.

Benzene as a Recognized Carcinogen and Myelotoxin

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms, and it is able to augment the risk for the onset of acute myeloid leukemia (AML), myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The causal relationship between occupational benzene exposure and AML has been established in previous studies (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Clinical Presentation and Diagnosis of Acute Myeloid Leukemia

Acute myeloid leukemia is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid precursor cells in the bone marrow and peripheral blood. Clinical presentation typically includes symptoms related to bone marrow failure, such as anemia (fatigue, pallor), thrombocytopenia (bleeding, bruising), and neutropenia (recurrent infections). Extramedullary involvement may occur, including gingival hypertrophy, skin infiltrates, or chloromas. Diagnosis is confirmed by bone marrow aspiration and biopsy demonstrating at least 20% blasts of myeloid lineage, along with immunophenotyping, cytogenetic analysis, and molecular testing to classify subtypes and guide treatment. The disease can arise de novo or secondary to prior chemotherapy, radiation, or exposure to myelotoxic agents such as benzene.

Benzene Pharmacology and Reported Adverse Effects

Benzene is a volatile organic compound widely used as an industrial solvent and a component of gasoline. Following inhalation or dermal absorption, benzene is metabolized primarily in the liver by cytochrome P450 enzymes to reactive intermediates, including benzene oxide, phenol, hydroquinone, and muconaldehyde. These metabolites can circulate to the bone marrow, where they exert toxic effects. Benzene is acknowledged as a myelotoxin, and chronic exposure can lead to hematotoxicity, including decreased blood cell counts, aplastic anemia, and increased risk of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Mechanistic Pathways Linking Benzene to Acute Myeloid Leukemia

Multiple mechanisms have been proposed for benzene-induced leukemogenesis. Possible mechanisms of benzene initiation of hematological tumors include a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies, suggesting a role for epigenetic effects (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene metabolites can induce DNA damage, chromosomal aberrations, and epigenetic changes such as altered gene expression. These early key events in the bone marrow can progress to myelodysplastic syndromes and ultimately AML. Prevention of these early events would lead to prevention of the apical adverse outcomes, the morbidity and mortality caused by MDS and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Risk Anchors: Adequacy of Warnings, Causation Considerations, and Timeline

The adequacy of warnings regarding benzene and AML is a critical risk anchor. Given the established causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/), regulatory agencies and employers have a responsibility to inform workers of these risks and implement exposure controls. However, the extent to which warnings have been effectively communicated and heeded may vary across industries and jurisdictions. For affected patients, causation-related considerations include the level and duration of benzene exposure, latency period, and presence of other risk factors. Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). In a national cohort from Switzerland, occupational exposure to benzene was associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). The timeline between exposure and documented harm can be years to decades, as AML typically develops after a latency period of several years following chronic benzene exposure. Early hematotoxic effects, such as decreased blood cell counts, may precede the onset of AML and serve as sentinel events. Findings from a meta-analysis indicated an elevated risk of AML in children exposed to benzene (odds ratio: 1.22, 95% confidence interval: 1.02-1.46) (https://pubmed.ncbi.nlm.nih.gov/41485753/), underscoring that even low-level environmental exposures may contribute to risk.

Conclusion

In summary, benzene is a recognized cause of acute myeloid leukemia, supported by epidemiological evidence, mechanistic plausibility, and clinical observations. The risk is particularly pronounced with occupational exposures at levels of 10 ppm or higher, but lower-level environmental exposures may also contribute. Adequate warnings and exposure prevention are essential to reduce the burden of benzene-induced AML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence that benzene causes acute myeloid leukemia?

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene can augment the risk for the onset of acute myeloid leukemia (AML), myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The causal relationship between occupational benzene exposure and AML has been established in previous studies (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

What are the mechanisms by which benzene causes leukemia?

Multiple mechanisms have been proposed for benzene-induced leukemogenesis, including genotoxic effects, oxidative stress and inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epigenetic effects may also play a role (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene metabolites can induce DNA damage, chromosomal aberrations, and epigenetic changes that progress to myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

What is the latency period between benzene exposure and AML?

The timeline between exposure and documented harm can be years to decades, as AML typically develops after a latency period of several years following chronic benzene exposure. Early hematotoxic effects, such as decreased blood cell counts, may precede the onset of AML and serve as sentinel events.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.